Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Parkside Financial Bank & Trust

Parkside Financial Bank & Trust lowered its stake in Illumina, Inc. (NASDAQ:ILMN) by 29.6% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 319 shares of the life sciences company’s stock after selling 134 shares during the quarter. Parkside Financial Bank & Trust’s holdings in Illumina were worth $44,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Linden Thomas Advisory Services LLC grew its stake in Illumina by 1.8% in the 4th quarter. Linden Thomas Advisory Services LLC now owns 9,242 shares of the life sciences company’s stock valued at $1,287,000 after acquiring an additional 165 shares during the period. Jennison Associates LLC purchased a new position in Illumina in the 4th quarter valued at $24,566,000. Duality Advisers LP lifted its holdings in Illumina by 152.5% in the 4th quarter. Duality Advisers LP now owns 21,651 shares of the life sciences company’s stock valued at $3,015,000 after purchasing an additional 13,076 shares in the last quarter. North Star Asset Management Inc. lifted its holdings in Illumina by 29.3% in the 4th quarter. North Star Asset Management Inc. now owns 37,449 shares of the life sciences company’s stock valued at $5,214,000 after purchasing an additional 8,486 shares in the last quarter. Finally, Sumitomo Mitsui DS Asset Management Company Ltd lifted its holdings in Illumina by 1.7% in the 4th quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 14,073 shares of the life sciences company’s stock valued at $1,960,000 after purchasing an additional 239 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Insider Buying and Selling at Illumina

In other news, CEO Jacob Thaysen bought 7,330 shares of the company’s stock in a transaction on Thursday, February 22nd. The stock was bought at an average cost of $135.29 per share, with a total value of $991,675.70. Following the transaction, the chief executive officer now directly owns 14,861 shares in the company, valued at approximately $2,010,544.69. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 0.17% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of research analysts have weighed in on ILMN shares. StockNews.com upgraded Illumina from a “hold” rating to a “buy” rating in a report on Friday, February 16th. Royal Bank of Canada restated an “outperform” rating and issued a $253.00 price objective on shares of Illumina in a report on Tuesday, April 9th. TD Cowen lowered Illumina from an “outperform” rating to a “market perform” rating and set a $144.00 price target on the stock. in a report on Thursday, January 4th. Barclays lifted their price target on Illumina from $85.00 to $100.00 and gave the stock an “underweight” rating in a report on Wednesday, April 10th. Finally, HSBC lowered Illumina from a “buy” rating to a “hold” rating in a report on Tuesday, January 16th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, Illumina has a consensus rating of “Hold” and an average target price of $167.70.

Illumina Stock Up 1.0 %

Shares of ILMN opened at $122.28 on Friday. Illumina, Inc. has a 12-month low of $89.00 and a 12-month high of $213.91. The company’s 50-day moving average price is $131.51 and its 200 day moving average price is $127.39. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.29 and a current ratio of 1.66.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, February 8th. The life sciences company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.13. The company had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.09 billion. Illumina had a positive return on equity of 2.20% and a negative net margin of 25.78%. Illumina’s revenue was up 3.6% compared to the same quarter last year. During the same period in the previous year, the company posted $0.14 EPS. Equities research analysts expect that Illumina, Inc. will post 0.91 EPS for the current fiscal year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.